Skip to content
drillr.ai
Sign up

PODD

INSULET CORP

NASDAQ · Healthcare · Medical - Devices · US

$141.96
+0.61%
Ask drillr

  • Oct 12, 2026, 11:00 UTC

    Insulet announced the U.S. full market release of Omnipod Discover, a web-based data platform for Omnipod 5 users, caregivers and healthcare providers.

    Source:

  • Oct 1, 2026, 11:00 UTC

    Insulet Corporation announced it will report its third quarter 2026 financial results on November 4, 2026, before market open, with a conference call at 8:00 a.m. Eastern Time.

    Source:

  • Sep 30, 2026, 23:59 UTC

    Middlesex Community College received $2,179,977 from the Massachusetts Life Sciences Center to support 169 training seats in its Pathmaker Robotics and Automation Program, part of over $5.2 million in Pathmaker awards announced by Gov. Maura Healey and the MLSC on Sept. 17 to expand life sciences workforce training in Massachusetts.

    Source:

  • Sep 21, 2026, 21:07 UTC

    Insulete Corp amended its credit agreement, replacing $475 million of existing Term B Loans with new Term B Loans at a reduced interest rate margin and increasing revolving credit commitments by $250 million to $750 million.

  • Sep 10, 2026, 20:07 UTC

    Insulin delivery company Insulet Corp announced that board member Michael R. Minogue departed from its Board of Directors effective September 15, 2026.

  • Sep 10, 2026, 20:07 UTC

    Insulin delivery company Insulet Corp announced that board member Timothy J. Scannell departed from its Board of Directors effective September 3, 2026, for health reasons.

  • Aug 25, 2026, 07:57 UTC

    Algert Global LLC increased its stake in Insulet Corporation by 75.7% during the second quarter, acquiring 62,277 additional shares, as disclosed in a 13F filing.

    Source:

  • Aug 20, 2026, 07:18 UTC

    Aurora Investment Counsel purchased a new stake of 14,672 shares in Insulet Corporation, valued at approximately $2,234,000, as disclosed in a 13F filing.

    Source:

  • Aug 13, 2026, 18:40 UTC

    A securities class action lawsuit was filed against Insulet Corporation alleging it misled investors about the safety and reliability of its insulin delivery products.

    Source:

  • Aug 6, 2026, 01:11 UTC

    Insulet Corporation issued guidance for Q3 2026 and full-year 2026 revenue growth, while cutting full-year revenue expectations due to weaker Type 2 diabetes user retention.

    Source:

  • Aug 5, 2026, 11:00 UTC

    Insulet Corporation reported its financial results for the second quarter ended June 30, 2026, with revenue of $801.7 million, up 23.5% year-over-year, exceeding its guidance range.

    Source:

  • Aug 3, 2026, 08:37 UTC

    A class action lawsuit was filed against Insulet Corporation for alleged violations of U.S. securities laws, and the DJS Law Group is reminding investors of the case.

    Source:

  • Jul 31, 2026, 07:08 UTC

    A class action lawsuit was filed against Insulet Corporation for alleged securities law violations under the Securities Exchange Act of 1934.

    Source:

  • Jul 24, 2026, 10:36 UTC

    A class action lawsuit has been filed against Insulet Corporation and certain senior executives for securities fraud.

    Source:

  • Jul 14, 2026, 07:00 UTC

    Insulet Corporation announced a global partnership with Calm to provide emotional well-being resources for the diabetes community.

    Source:

  • Jul 12, 2026, 15:10 UTC

    A securities class action lawsuit was filed against Insulet Corporation alleging securities fraud between February 21, 2025 and May 26, 2026.

    Source:

  • Jul 6, 2026, 17:36 UTC

    The U.S. Food and Drug Administration classified Insulet Corp.'s recall of certain Omnipod insulin delivery pods as a Class I recall, the most serious classification, due to risk of serious injury or death.

    Source:

  • Jun 25, 2026, 00:00 UTC

    Jonathan J. Mazelsky was appointed as a Class II director of Insulet Corp, effective July 1, 2026.

  • Jun 8, 2026, 03:44 UTC

    Insulet Corporation launched significant enhancements to its Omnipod 5 Automated Insulin Delivery System in the US, including a new 100 mg/dL Target Glucose option and integration with Abbott's FreeStyle Libre 3 Plus sensor.

    Source:

  • Jun 6, 2026, 12:00 UTC

    Insulet Corporation reveals new data supporting its Omnipod 6 and fully closed-loop AID systems.

    Source:

  • Jun 3, 2026, 11:00 UTC

    Insulet Corporation rolled out an enhanced Omnipod 5 algorithm in the U.S. and expanded its compatibility with Abbott's FreeStyle Libre 3 Plus sensor.

    Source: